Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
abbvie
7
×
biotech
boston blog main
boulder/denver blog main
boulder/denver top stories
cancer
7
×
detroit blog main
detroit top stories
indiana blog main
indiana top stories
life sciences
national
national blog main
national top stories
7
×
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
7
×
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
boston top stories
startups
astrazeneca
clinical trials
eli lilly
alzheimer's disease
cancer immunotherapy
deals
fda
merck
biogen
bristol-myers squibb
What
bio
roundup
7
×
drug
companies
week
acquisitions
ceo
conference
daniel
debut
gilead
moves
nash
news
o’day
sciences
abbvie’s
alzheimer’s
announced
annual
approval
approved
assessed
attention
barbecuing
biggest
biogen’s
biopharmaceutical
biotech
black
build
buy
camping
cardiologist
center
check
cholesterol
collabs
communities
company’s
Language
unset
Current search:
roundup
×
cancer
×
" national top stories "
×
" san francisco blog main "
×
abbvie
×
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More
@xconomy.com
4 years ago
Bio Roundup: Cholesterol Check, J&J’s Opioid Hit, AbbVie’s Flop & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More